Despite the impact of COVID, the company forged ahead with its priorities, including expanding its U.S. business and accelerating its innovation pipeline.
The company's orthopedic sales declined -49% in 2Q20 but recovered significantly from -80% declines in April. Integra expects improvement through 2H20.
The company's sales improved throughout 2Q20 but exited June with declines in the mid-teens. Orthofix remains cautious about second-half unpredictability.
Our site uses cookies to allow easier access for Members and subscribers and to improve our site. You agree to our use of cookies by closing this message box or continuing to use our site.OkRead more